{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:23:04Z","timestamp":1793334184748,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,1,1]]},"DOI":"10.1001\/jamaoncol.2019.4782","type":"journal-article","created":{"date-parts":[[2019,9,29]],"date-time":"2019-09-29T11:30:31Z","timestamp":1569756631000},"page":"116","source":"Crossref","is-referenced-by-count":920,"title":["The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor\u2013Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy\u2014MONARCH 2"],"prefix":"10.1001","volume":"6","author":[{"suffix":"Jr","given":"George W.","family":"Sledge","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[{"name":"Universitaire Ziekenhuizen Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Saitama Cancer Center, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pivot","sequence":"additional","affiliation":[{"name":"Centre Paul Strauss, INSERM 110, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Burdaeva","sequence":"additional","affiliation":[{"name":"Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Okera","sequence":"additional","affiliation":[{"name":"Adelaide Cancer Centre, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[{"name":"National Hospital Organization, Osaka National Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"University of Vermont Cancer Center, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Koh","sequence":"additional","affiliation":[{"name":"Kaiser Permanente, Bellflower, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Grischke","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PierFranco","family":"Conte","sequence":"additional","affiliation":[{"name":"DiSCOG, University of Padova and Medical Oncology 2, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Barriga","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Hurt","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Frenzel","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Johnston","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Llombart-Cussac","sequence":"additional","affiliation":[{"name":"Hospital Arnau Vilanova, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"25","key":"coi190093r1","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy.","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi190093r2","doi-asserted-by":"publisher","first-page":"990","DOI":"10.5306\/wjco.v5.i5.990","article-title":"Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.","volume":"5","author":"Milani","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"25","key":"coi190093r3","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline.","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi190093r4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10549-013-2711-y","article-title":"Prognosis of metastatic breast cancer subtypes: the hormone receptor\/HER2-positive subtype is associated with the most favorable outcome.","volume":"141","author":"Lobbezoo","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"coi190093r5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"coi190093r6","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase ii study of abemaciclib, a CDK4 and CDK6 Inhibitor, as a single agent, in patients with refractory HR+\/HER2- metastatic breast cancer.","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"coi190093r7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13058-018-1050-7","article-title":"Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.","volume":"20","author":"Hortobagyi","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"4","key":"coi190093r8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1056\/NEJMe1906236","article-title":"Achieving improved survival outcomes in advanced breast cancer.","volume":"381","author":"Rugo","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"coi190093r9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine.","volume":"32","author":"Gelbert","year":"2014","journal-title":"Invest New Drugs"},{"issue":"32","key":"coi190093r10","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer.","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi190093r11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"coi190093r12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer.","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"coi190093r13","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer.","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"coi190093r14","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","article-title":"Prognostic factors in 1,038 women with metastatic breast cancer.","volume":"19","author":"Largillier","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"coi190093r15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-016-4066-7","article-title":"Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis.","volume":"161","author":"Leone","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"coi190093r16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41523-018-0094-2","article-title":"Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.","volume":"4","author":"Di Leo","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"coi190093r17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.breast.2017.01.001","article-title":"Corrigendum to \u201c3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)\u201d [Breast 31 (February 2017) 244-259].","volume":"32","author":"Cardoso","year":"2017","journal-title":"Breast"},{"issue":"12","key":"coi190093r18","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1093\/annonc\/mdx036","article-title":"3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"coi190093r19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer.","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"coi190093r20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update.","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"coi190093r21","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"coi190093r22","first-page":"1049","article-title":"Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.","volume":"36","author":"Kaufman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi190093r23","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1186\/s12885-018-4978-1","article-title":"Selecting the optimal position of CDK4\/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.","volume":"18","author":"van Ommen-Nijhof","year":"2018","journal-title":"BMC Cancer"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2752266\/jamaoncology_sledge_2019_oi_190093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T11:02:00Z","timestamp":1578567720000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2752266"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,1]]}}}